Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Shoals Technologies Group Fourth Quarter 2025 Earnings Call - Record Backlog Powers 2026 Growth, but Margins Face Tariff and Legal Headwinds
Shoals closed Q4 with strong top-line momentum and a company record backlog, but profit rates slipped as tariffs, elevated legal spend, and product mix pressure margins. Revenue was $148.3 million in ...
- Q4 revenue $148.3 million, up 38.6% year over year, driven by domestic project volume and newer channels.
- Full year 2025 revenue trajectory accelerated, with management saying annual revenue roughly doubled since IPO to about $475 million.
- Record backlog and awarded orders (BLAO) reached ~$747.6 million, an 18% year over year increase, with ~$603 million planned for shipment in 2026.
- +12 more takeaways
Planet Fitness Q4 2025 Earnings Call - Record Q4 openings and member gains, but 2026 guide tempered by reequip cycle and club sale
Planet Fitness closed 2025 with 20.8 million members and nearly 2,900 clubs after a banner year of expansion and member growth. The company opened 181 clubs in 2025, including a record 104 in Q4, adde...
- Planet Fitness ended 2025 with ~20.8 million members and nearly 2,900 clubs, demonstrating scale and reach.
- The company opened 181 new clubs in 2025, including a record 104 in Q4, the highest quarterly openings in company history.
- Net new members were 1.1 million in 2025, a 10% increase versus 2024 despite the first full year of higher Classic Card pricing.
- +12 more takeaways
Fulcrum Therapeutics Q4 2025 Earnings Call - Pociredir 20 mg lifts mean HbF to 19.3% with >50% reaching >=20% in 12 weeks
Fulcrum reported full 12-week data from the 20 mg cohort of the Phase 1b PIONEER trial. Pociredir produced a rapid, sizable rise in fetal hemoglobin, a doubling of F cells, reductions in hemolysis mar...
- Pociredir 20 mg once daily produced a mean absolute HbF increase of 12.2 percentage points, rising from 7.1% at baseline to 19.3% at week 12.
- Seven of 12 evaluable patients, 58%, achieved at least 20% absolute HbF by week 12, a threshold historically linked to clinical protection.
- F cell fraction roughly doubled, from about 31% at baseline to 63% at week 12, indicating broader red cell coverage.
- +12 more takeaways
AxoGen Q4 2025 Earnings Call - FDA BLA for Avance Clears Path to Scale, but Biologic Mix Will Squeeze Near-Term Margins
AxoGen closed 2025 with strong top line momentum and a strategic milestone that changes the game. Full year revenue rose 20.2% to $225.2 million, adjusted EBITDA jumped 41% to $27.9 million, and the D...
- Q4 revenue was $59.9 million, up 21.3% year over year; full year 2025 revenue was $225.2 million, up 20.2% from 2024.
- Adjusted EBITDA for 2025 rose 41% to $27.9 million, and adjusted EBITDA margin improved to 12.4% for the year, up 180 basis points year over year.
- AxoGen completed an upsized public offering in January, raising $133.3 million net, used $69.7 million to fully retire its term loan, leaving a cleaner capital structure and increased financial flexibility.
- +12 more takeaways
First Watch Restaurant Group Inc. Fourth Quarter Fiscal 2025 Earnings Call - Record openings and margin resilience set up 2026 growth
First Watch closed fiscal 2025 with a splash: system revenue jumped more than 20% and same-restaurant sales were positive, even as industry traffic softened. The company opened 64 restaurants in 2025,...
- System revenue grew more than 20% in fiscal 2025; fourth quarter revenue was $316.4 million, up 20.2% year-over-year.
- Fiscal 2025 same-restaurant sales rose 3.6% for the year; fourth quarter same-restaurant sales were +3.1% while same-restaurant traffic in Q4 was negative 1.9%.
- First Watch opened 64 new restaurants in 2025, the largest opening class in the company’s history, finishing the year with 633 restaurants across 32 states.
- +13 more takeaways
Kiniksa Pharmaceuticals Q4 2025 Earnings Call - Arcalyst sales accelerate, company profitable and guiding to $900-920M in 2026
Kiniksa closed 2025 on a clear upward trajectory, driven by accelerating adoption of Arcalyst for recurrent pericarditis. Fourth quarter Arcalyst product revenue hit $202.1 million, up 65% year over y...
- Arcalyst product revenue was $202.1 million in Q4 2025, up 65% year over year, and $677.6 million for full year 2025, up 62% year over year.
- Kiniksa reported net income of $14.2 million in Q4 2025 versus a net loss of $8.9 million in Q4 2024, and net income of $59.0 million for full year 2025 versus a net loss of $43.2 million in 2024.
- The company ended 2025 with $414.1 million in cash and generated $170.4 million of net cash during the year, and expects to remain cash flow positive on an annual basis under the current plan.
- +12 more takeaways
Elanco Animal Health Q4 2025 Earnings Call - Innovation Momentum (Credelio Quattro, Zenrelia) Fuels Faster Deleveraging and Raised 2026 Innovation Target
Elanco closed 2025 with clear momentum: 9% organic constant-currency revenue growth in Q4 and a full-year innovation haul of $892 million. Management raised the 2026 innovation target to $1.15 billion...
- Q4 2025 organic constant-currency revenue grew 9%, driven by US Farm Animal (+17%) and US Pet Health (+10%).
- Full-year 2025 innovation revenue reached $892 million, with Q4 the largest innovation quarter to date.
- Management raised the 2026 innovation target to $1.15 billion, implying at least $250 million of incremental innovation revenue year-over-year.
- +12 more takeaways
Fresenius Medical Care Q4 2025 Earnings Call - Exceptional Q4 lifts margins, 2026 flagged as a transition year driven by 5008X rollout and TDAPA phasing
Fresenius Medical Care closed 2025 with a punchy fourth quarter, delivering organic revenue growth of 8% and a 430 basis point margin expansion that pushed adjusted operating income up 53% year over y...
- Company hit upper end of its 2025 outlook, finishing the year with group margin for 2025 at 11.3% and a standout Q4 margin of 13.9%, up 430 basis points year over year.
- Q4 performance: organic revenue growth of 8% and adjusted operating income up 53% on a constant currency basis, driven by Care Delivery and Value-Based Care.
- FME Reignite strategy launched, Value-Based Care carved out as third segment, which generated over EUR 2 billion in revenue in 2025 and reached break-even for the year (EUR 3 million).
- +12 more takeaways
China Yuchai International Limited Second Half 2025 & FY2025 Earnings Call - Heavy‑duty engines and data‑center gensets drove a sharp lift in sales and margins
China Yuchai reported a clear acceleration in the back half of 2025, with management pointing to heavy‑duty and high‑horsepower engines, and a surge in data‑center genset demand, as the main profit en...
- Second half 2025 revenue rose 33.5% year‑over‑year to RMB 11.8 billion, with gross profit up 58.4% to RMB 2.2 billion and gross margin at 18.9%.
- Management reported operating profit in H2 2025 of RMB 469.2 million and H2 operating margin of ~4.0%, driving a large jump in H2 profitability versus 2024.
- Full‑year 2025 results showed strong unit growth: total engines sold reached 461,309 units, up 29.4% year‑over‑year; H2 units were 210,913, up 28.7% versus prior H2.
- +11 more takeaways
Interface, Inc. Q4 2025 Earnings Call - One Interface strategy drives record sales, margin expansion and launches Noravant
Interface closed 2025 with a record year: net sales and adjusted operating income hit all-time highs as the One Interface commercial model, automation investments, and cross-category selling powered v...
- Record 2025 performance, with full-year currency-neutral net sales up approximately 4% and adjusted gross profit margin expanding to 39%.
- Fourth quarter net sales of $349.4 million, up 4.3% reported, 1.6% currency-neutral; Q4 adjusted gross profit margin 38.6%, up 169 basis points year-over-year.
- Adjusted operating income and adjusted EBITDA reached record highs for the year, with full-year adjusted operating income $173.8 million (up 22.9%) and adjusted EBITDA $217.9 million (up 15.3%).
- +11 more takeaways